Oak Hill Bio and RACC III Propose Rare-Disease Combination
Oak Hill Bio and Research Alliance Corporation III agreed to a business combination intended to create a publicly listed rare-disease company and provide approximately $175 million in gross proceeds. The capital is expected to…
